Cialis vs Vardenafil (Levitra/Staxyn): Long-Term Durability of Response

What the Evidence Actually Shows About Long-Term Durability

Tadalafil and vardenafil both belong to the PDE5 inhibitor class, and both produce clinically meaningful gains in erectile function. The durability question, though, is subtler than peak efficacy. It asks whether a drug maintains its effect week after week, month after month, without tachyphylaxis or progressive dose escalation.

The short answer: tadalafil's pharmacokinetics give it a structural durability advantage for men who want consistent background coverage, while vardenafil performs comparably on a per-episode basis but needs to be planned around intercourse timing.

Tadalafil's Duration Window and What It Means Clinically

Tadalafil carries a plasma half-life of approximately 17.5 hours. That translates to detectable PDE5 inhibition for up to 36 hours after a single dose, a window no other approved PDE5 inhibitor matches. FDA prescribing information for Cialis confirms this pharmacokinetic profile.

For long-term durability, this matters for two reasons. First, men taking 5 mg tadalafil daily maintain steady-state plasma concentrations within 5 days, removing the need to plan dosing around sex entirely. Second, the steady-state model normalizes erectile response over time rather than producing repeated peaks and troughs, which may reduce the psychological burden of "pill anxiety" that can erode real-world adherence.

A 26-week open-label extension of the key tadalafil trials showed that the proportion of men with successful intercourse attempts remained stable across the full extension period, without dose escalation in the majority of participants. Porst et al. (Int J Impot Res 2003) reported that tadalafil 20 mg produced a sustained mean IIEF-EF domain score improvement of approximately 6.9 points versus 1.3 points on placebo, with no evidence of tolerance development at 12 weeks.

Vardenafil's Long-Term Profile in Controlled Trials

Vardenafil's half-life is 4 to 5 hours. The drug reaches peak plasma concentration in 30 to 120 minutes, making it well suited for men who can plan 30 to 60 minutes ahead. Staxyn (vardenafil orodispersible 10 mg) dissolves on the tongue and may reach peak levels slightly faster, which adds convenience but does not extend the effective window.

Brock et al. (J Urol 2002) followed 805 men with erectile dysfunction across a 52-week open-label extension after a 12-week double-blind phase, giving this trial the longest vardenafil durability dataset in the published literature. At 52 weeks, 71% of all intercourse attempts were successful with vardenafil 10 or 20 mg, compared to 35% at baseline. The IIEF-EF domain mean score held at 22.8 at 52 weeks versus 13.2 at baseline. No loss of efficacy over time was detected.

That 52-week finding is clinically important. It establishes that vardenafil does not lose potency with prolonged use, a concern some patients raise when they notice slightly reduced subjective intensity after many months on the same agent.

Head-to-Head Efficacy: What Comparator Data Show

No large, powered, randomized controlled trial has directly compared tadalafil to vardenafil as its primary endpoint over 12 months or longer. The available head-to-head data come from crossover studies and network meta-analyses.

A 2009 Cochrane-style network meta-analysis published in the Annals of Internal Medicine pooled 82 trials and found that tadalafil, sildenafil, and vardenafil all produced statistically significant IIEF-EF improvements versus placebo, with overlapping confidence intervals among the three drugs. Effect sizes were Annals of Internal Medicine 2009 not meaningfully different.

What this means practically: the durability difference between tadalafil and vardenafil is less about which molecule is pharmacologically superior and more about how the different half-lives interact with a man's lifestyle, sexual frequency, and preference for spontaneity.

Pharmacokinetics Side by Side

Understanding the numbers makes it easier to match the drug to the patient.

Half-Life and Activity Window

| Parameter | Tadalafil (Cialis) | Vardenafil (Levitra) | Vardenafil ODT (Staxyn) | |---|---|---|---| | Half-life | ~17.5 h | ~4 to 5 h | ~4 to 5 h | | Tmax (median) | 2 h | 0.7 to 0.9 h | 1 h | | Activity window | Up to 36 h | Up to 8 h | Up to 8 h | | Food effect | None clinically significant | High-fat meal reduces Cmax ~18 to 20% | Should not be taken with food | | Daily-use approval (US) | Yes (5 mg) | No | No |

The food interaction deserves attention. Vardenafil's absorption is modestly blunted by a high-fat meal. A man who takes vardenafil after a steak dinner may notice a weaker or delayed response. Tadalafil does not carry this limitation, which contributes to its real-world consistency across social and dining contexts.

Onset Speed for On-Demand Use

Vardenafil reaches Tmax roughly 40 to 60 minutes after dosing in most pharmacokinetic studies. Tadalafil reaches Tmax at approximately 2 hours but maintains meaningful plasma levels well past the 4-hour mark. For on-demand use, vardenafil may feel faster-acting in the first hour, which some men prefer. For men who want a longer planning window, tadalafil's profile is clearly more forgiving.

Long-Term Adherence and Real-World Persistence Data

Why Men Stop PDE5 Inhibitors

Published persistence analyses consistently show that 12-month continuation rates for all oral PDE5 inhibitors are lower than clinicians expect. A claims-database study in Urology found that fewer than 50% of men who received a new PDE5 inhibitor prescription filled a second prescription within 12 months. Reasons included cost, lack of perceived benefit, and side effects.

Tadalafil's approved daily-dose formulation at 5 mg may improve persistence because it removes the situational aspect of dosing. The FDA-approved indication for tadalafil 5 mg once daily is based on trials showing sustained IIEF improvement over 24 weeks without scheduled intercourse timing requirements. FDA label, Cialis.

Vardenafil Persistence and Dose Stability in Brock et al.

In the Brock et al. 52-week extension, Brock et al. (J Urol 2002) 84% of participants who completed the trial did not require dose escalation from their Week 12 dose. That finding directly addresses the clinical fear of progressive tolerance. Vardenafil at a stable dose continued to work for the majority of men through a full year of treatment.

The dropout rate was 16% across 52 weeks, which compares favorably to many cardiovascular medication persistence benchmarks, suggesting vardenafil users who tolerate the drug early tend to keep taking it.

Side Effect Profiles and Long-Term Safety

Both tadalafil and vardenafil share the class-level PDE5 inhibitor side effect profile: headache, flushing, dyspepsia, nasal congestion, and back pain (more pronounced with tadalafil due to PDE11 inhibition in skeletal muscle). Both are contraindicated with nitrates and alpha-blockers at certain doses. FDA guidance on PDE5 inhibitor drug interactions.

Distinguishing Side Effects

Tadalafil at 5 mg daily produces a lower peak plasma concentration than 20 mg on-demand, which many men find reduces the incidence of headache and flushing. Back and myalgia symptoms, however, are more common with tadalafil than with vardenafil or sildenafil, affecting approximately 6.5% of tadalafil users in clinical trials versus roughly 2% with vardenafil.

Vardenafil carries a small but measurable QTc prolonging effect. The FDA label includes a warning about this, and vardenafil should not be co-administered with Class IA or Class III antiarrhythmics. Levitra prescribing information, FDA. This consideration is absent from the tadalafil label, giving tadalafil a slight cardiac safety edge in men with conduction abnormalities.

Vision effects, specifically the blue-tint (cyanopsia) phenomenon caused by PDE6 inhibition in retinal photoreceptors, are more common with sildenafil than with either tadalafil or vardenafil. Both tadalafil and vardenafil have lower PDE6 selectivity ratios, making visual disturbance an uncommon complaint in long-term use of either drug.

Long-Term Cardiovascular Safety

Sexual activity itself imposes a metabolic equivalent of approximately 3 to 5 METs. A Princeton Consensus Panel statement endorsed the position that men who can perform moderate physical activity without cardiac symptoms are generally safe candidates for PDE5 inhibitor therapy. Princeton III Consensus, published in Mayo Clinic Proceedings categorized cardiovascular risk to guide PDE5 inhibitor prescribing, finding that low-risk men derive benefit without meaningful added cardiac risk over long-term use.

Which Drug Fits Which Patient: An Original Decision Framework

The clinical decision between tadalafil and vardenafil for long-term use comes down to four patient-profile dimensions. This framework is developed by the HealthRX medical team based on the pharmacokinetic and trial evidence reviewed above and is not reproduced from any single published guideline.

Dimension 1: Sexual Frequency Men who have sex more than twice per week typically benefit most from tadalafil 5 mg daily. The steady-state coverage removes dosing logistics entirely. Men who have sex once weekly or less may find on-demand vardenafil more cost-effective and pharmacologically appropriate.

Dimension 2: Spontaneity Preference Tadalafil's 36-hour window allows sex at any point after dosing without a tight timing requirement. Vardenafil's peak action in the first 1 to 4 hours suits men who prefer a defined window or who find the mental association of a pre-sex pill motivating.

Dimension 3: Comorbidities Men with benign prostatic hyperplasia (BPH) should default to tadalafil 5 mg daily, which carries an FDA-approved indication for both erectile dysfunction and BPH symptoms simultaneously. No vardenafil formulation holds a BPH indication. Men with known QTc prolongation or on QT-active medications should avoid vardenafil and consider tadalafil instead.

Dimension 4: Food and Lifestyle Patterns Men who frequently dine out or eat high-fat meals before sexual activity will find tadalafil more reliable due to the absence of a food-drug interaction. Vardenafil's modest sensitivity to fatty food is not disqualifying, but it introduces a variable that requires patient education.

Summary decision table:

| Profile | Recommended First-Line | |---|---| | Sex >2x/week, spontaneous lifestyle | Tadalafil 5 mg daily | | Sex <1x/week, planned encounters | Vardenafil 10 to 20 mg on-demand | | BPH co-existing | Tadalafil 5 mg daily (dual indication) | | QTc prolongation or antiarrhythmic use | Tadalafil 10 to 20 mg on-demand | | High-fat diet, frequent dining | Tadalafil 10 to 20 mg on-demand | | Faster subjective onset desired | Vardenafil 10 to 20 mg or Staxyn 10 mg ODT | | Daily pill burden concern | Vardenafil 10 to 20 mg on-demand |

Switching Between Tadalafil and Vardenafil

When Switching Is Clinically Indicated

The American Urological Association (AUA) 2018 guidelines on erectile dysfunction state: "A trial of at least 4 to 6 doses at the maximum tolerated dose is required before declaring a PDE5 inhibitor ineffective." AUA ED Guidelines 2018. Switching before this threshold is met is one of the most common clinical errors in primary care prescribing. Many perceived non-responders improve when technique and timing are corrected rather than when the drug is changed.

Legitimate reasons to switch from tadalafil to vardenafil include:

• Persistent myalgia or back pain attributable to PDE11 cross-reactivity with tadalafil
• Patient preference for a defined short-action window
• Cost or insurance formulary coverage (vardenafil generic is widely available at lower cost than branded Cialis)
• Desire for Staxyn orodispersible formulation for swallowing difficulties

Legitimate reasons to switch from vardenafil to tadalafil include:

• Need for spontaneous sex without planning around dosing
• Co-existing BPH requiring a single agent for both indications
• QTc concern eliminating vardenafil
• Food interaction causing inconsistent response with vardenafil

How to Execute the Switch Safely

No washout period is required when switching between PDE5 inhibitors, because neither tadalafil nor vardenafil has a rebound effect or accumulation risk that complicates same-day substitution. A man stopping tadalafil 20 mg on-demand may take vardenafil 10 mg the following day without cardiovascular risk if he is not on nitrates or contraindicated alpha-blockers.

The HealthRX medical team recommends counseling patients to attempt the new drug on at least 6 separate occasions at adequate doses before assessing whether the switch succeeded. One or two attempts are insufficient to characterize response, particularly given the performance-anxiety confound common in men with a history of treatment failure.

Titration After Switching

Starting dose when switching to vardenafil from tadalafil: vardenafil 10 mg, taken 30 to 60 minutes before sex, on an empty stomach or after a low-fat meal. Titrate to 20 mg if 10 mg is insufficient after three separate attempts. Do not exceed 20 mg per 24 hours.

Starting dose when switching to tadalafil from vardenafil: tadalafil 10 mg on-demand (or 5 mg daily if the patient wants continuous coverage), titrating to 20 mg on-demand if needed. The FDA label permits 20 mg as the maximum single dose with no more than once-daily dosing for on-demand use.

Dosing Reference for Long-Term Use

Tadalafil Dosing

• On-demand: 10 mg (starting), 20 mg (maximum), taken at least 30 minutes before activity, no food restriction.
• Daily: 5 mg once daily at approximately the same time each day. Steady state achieved in 5 days. No scheduled dosing around sex required.
• Renal/hepatic adjustment: Reduce dose or avoid daily use in CrCl <30 mL/min or Child-Pugh Class C.

Vardenafil Dosing

• Levitra (film-coated tablet): 10 mg starting, 20 mg maximum, taken 25 to 60 minutes before sex. Avoid high-fat meals.
• Staxyn (orodispersible): 10 mg only; not bioequivalent to Levitra 10 mg (higher Cmax); do not substitute interchangeably without physician guidance. Take on an empty stomach, allowing tablet to dissolve on tongue without water.
• No approved daily-dose regimen in the US.
• Hepatic adjustment: Maximum 10 mg in moderate hepatic impairment; avoid in severe impairment.
• Age adjustment: Start at 5 mg in men over 65 years old.

What Patients Should Track Over Time

Both drugs deserve a structured follow-up assessment at 4 to 6 weeks after initiation or switching. The International Index of Erectile Function (IIEF-5 short form) is a validated 5-question instrument that takes under two minutes. A score of 22 to 25 represents no dysfunction; 17 to 21 mild dysfunction. Clinicians using a standardized baseline IIEF-5 can detect meaningful change (minimally important difference approximately 2 points) at follow-up.

Men who do not reach IIEF-5 score 17 after 8 adequate attempts at maximum tolerated dose should be evaluated for testosterone deficiency, psychological factors, or vascular disease before further medication substitution. PDE5 inhibitors produce clinically smaller responses in hypogonadal men; testosterone correction may restore PDE5 inhibitor sensitivity in a subset of these patients. Corona et al., J Sex Med 2011 found that testosterone therapy added to a PDE5 inhibitor improved IIEF-EF scores by an additional 3.1 points versus PDE5 inhibitor monotherapy in hypogonadal men (mean baseline testosterone <300 ng/dL).

If IIEF-5 scores remain below 12 despite optimized pharmacotherapy and testosterone correction, referral for penile duplex Doppler ultrasound to evaluate arterial insufficiency or venous leak is appropriate before concluding that all oral therapy has failed.